Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH)

To better risk stratify patients, using baseline characteristics, to help optimise decision‐making for men with moderate‐to‐severe lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) through a secondary analysis of the Medical Therapy of Prostatic Symptoms (MTOPS) trial.

[1]  S. Akimoto,et al.  The natural history of benign prostatic hyperplasia. , 1997, Harvard men's health watch.

[2]  Sun Il Kim,et al.  Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia: an observational cohort study. , 2003, European urology.

[3]  J. Trachtenberg,et al.  Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion , 2005, Prostate Cancer and Prostatic Diseases.

[4]  C. Roehrborn,et al.  Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. , 1999, Urology.

[5]  M. Kattan,et al.  The Use of Nomograms for Selecting BPH Candidates for Dutasteride Therapy. , 2004, Reviews in urology.

[6]  C.J.H. Mann,et al.  Clinical Prediction Models: A Practical Approach to Development, Validation and Updating , 2009 .

[7]  David M. Kent,et al.  Using Internally Developed Risk Models to Assess Heterogeneity in Treatment Effects in Clinical Trials , 2014, Circulation. Cardiovascular quality and outcomes.

[8]  C. Roehrborn,et al.  Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. , 2006, The Journal of urology.

[9]  C. Roehrborn,et al.  The Progression of Benign Prostatic Hyperplasia: Examining the Evidence and Determining the Risk , 2001, European Urology.

[10]  M. Barry,et al.  Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association. , 1995, Medical care.

[11]  C. Roehrborn.  BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF‐ONE , 2008, BJU international.

[12]  Ying Qin,et al.  NIDDK data repository: a central collection of clinical trial data , 2006, BMC Medical Informatics Decis. Mak..

[13]  J. Parsons.  Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. , 2007, The Journal of urology.

[14]  M. Kattan,et al.  Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia. , 2006, Urology.

[15]  C. Roehrborn,et al.  The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. , 2003, The New England journal of medicine.

[16]  C. Roehrborn.  Definition of at‐risk patients: baseline variables , 2006, BJU international.

[17]  C. Roehrborn,et al.  Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. , 2006, The Journal of urology.

[18]  Matthew T. Haren,et al.  Risk factors for progression or improvement of lower urinary tract symptoms in a prospective cohort of men. , 2014, The Journal of urology.

[19]  David M Kent,et al.  Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal , 2010, Trials.

[20]  A. Araujo,et al.  Treatment status and progression or regression of lower urinary tract symptoms in a general adult population sample. , 2014, The Journal of urology.

[21]  Ralph B. D'Agostino,et al.  Evaluation of the Performance of Survival Analysis Models: Discrimination and Calibration Measures , 2003, Advances in Survival Analysis.

[22]  J. Trachtenberg.  Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression , 2005, BJU international.

[23]  Ewout W Steyerberg,et al.  Estimating treatment effects for individual patients based on the results of randomised clinical trials , 2011, BMJ : British Medical Journal.

[24]  M. Emberton,et al.  Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk , 2007, BJU international.

[25]  J H Wasson,et al.  5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. , 1998, The Journal of urology.

[26]  Siep Thomas,et al.  Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study. , 2009, The Journal of urology.

[27]  M. Barry,et al.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.

[28]  C. Roehrborn,et al.  The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. , 2009, European urology.